Only a partnership involving all major stakeholder groups can effectively address the challenges of precision medicine. Based on this belief the participation of founding members representing patient advocacy groups and industry was secured. In addition to this, there is an ongoing effort to seek and add new members from the regulatory, medical, non-profit and academic sectors and beyond, as well as reinforce the participation of the patient community among those who have an interest, expertise in and impact on the different aspects of precision medicine.
The Program is governed by a Board, which represents members and makes the major strategic decisions for the organization.
In order to maintain a patient-centric approach and ensure financial and strategic independence of the Program, Members have decided to cap the participation of industry at maximum 40% on the Board. Equally, a minimum representation of 40% of patients is required. Other stakeholder types such as healthcare professionals are also represented on the Board. The representation requirements may evolve as the program matures to reinforce the balanced and shared decision making approach.
Read more about the FT3 Governance here.
Key principles for collaborative leadership
Balanced representation of stakeholders for transparency, inclusiveness, diversity and credibility. Only a balanced inclusion of all stakeholders, also reflected in decision-making structures and agile operations, deliver results.
The Program is non-competitive and does not exist to promote the interests of any specific organization, their brands or products.
Members and contributors must always work for the interest of the common goal, leaving individual interests at the door.